美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Militia Long/Short Equity ETF

36.45

+0.51001.42%

盘后：36.450.00000.00%16:28 EDT

成交量：23.91万

成交额：865.00万

市值：4.33亿

市盈率：- -

高：36.45

开：36.05

低：35.92

收：35.94

52周最高：39.39

52周最低：25.85

股本：1,188.00万

流通股本：1,188.00万

量比：1.25

换手率：2.01%

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

君赛生物赴港IPO：核心产品数据平平且专利仍待审批递表前股东要求回购或转让股权

新股前瞻|布局TCE肿瘤疗法千亿蓝海，时迈药业能否博得市场青睐？

吉利德Anito-cel 神经毒性低，2年多发性骨髓瘤生存率高 | ASH25

iza-bren食管鳞癌Ⅲ期临床期中分析迎关键突破

每日经济新闻

一哥新高，要起风了

CPHI制药在线

药企豪赌肺癌下一代免疫“新药王”争夺赛已打响

招银国际：医药业关注布局思路更偏稳健低估值个股机会

安科生物披露创新药HuA21注射液在2025年欧洲肿瘤内科学会年会公布临床研究数据

FAK赛道处于爆发前夜！应世生物深耕布局，全球领跑

药明巨诺：国产病毒载体版倍诺达补充申请获国家药监局受理

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/ORR/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":36.45,"timestamp":1774987200000,"preClose":35.94,"halted":0,"volume":239079,"hourTrading":{"tag":"盘后","latestPrice":36.45,"preClose":36.45,"latestTime":"16:28 EDT","volume":885,"amount":32257.78,"timestamp":1774988934539,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.014190317195325685,"floatShares":11880000,"shares":11880000,"eps":0,"marketStatus":"已收盘","change":0.51,"latestTime":"03-31 16:00:00 EDT","open":36.05,"high":36.45,"low":35.92,"amount":8650004.8622,"amplitude":0.014747,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1775030400000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":35.94,"sharesOutstanding":12900000,"nav":36.22,"aum":430293600,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":36.0001,"preClose":35.94,"latestTime":"08:46 EDT","volume":23,"amount":828.27071,"timestamp":1774961178428,"change":0.0601,"changeRate":0.001672,"amplitude":0.000835},"postHourTrading":{"tag":"盘后","latestPrice":36.45,"preClose":36.45,"latestTime":"16:28 EDT","volume":885,"amount":32257.78,"timestamp":1774988934539,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.250118,"impliedVol":0.031,"impliedVolPercentile":0.069},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":11880000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.250118,"shares":11880000,"dividePrice":0,"high":36.45,"amplitude":0.014747,"preClose":35.94,"low":35.92,"week52Low":25.85,"pbRate":"--","week52High":39.39,"institutionHeld":0,"latestPrice":36.45,"eps":0,"divideRate":0,"volume":239079,"delay":0,"ttmEps":0,"open":36.05,"prevYearClose":34.16,"prevWeekClose":35.81,"prevMonthClose":39.08,"prevQuarterClose":34.16,"fiveDayClose":36.31,"twentyDayClose":37.32,"sixtyDayClose":34.4324},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2592502964","title":"君赛生物赴港IPO：核心产品数据平平且专利仍待审批 递表前股东要求回购或转让股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2592502964","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592502964?lang=zh_cn&edition=fundamental","pubTime":"2025-12-17 15:10","pubTimestamp":1765955400,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　近日，上海君赛生物股份有限公司正式向港交所递交招股说明书。招股书显示，公司专注于实体瘤创新细胞疗法的生物科技公司，其核心产品GC101为全球首款无需高强度清淋化疗及IL-2给药的肿瘤浸润淋巴细胞疗法，承载着成为国内首个获批TIL疗法的期望。　　TIL细胞疗法是指通过离体激活来源于肿瘤组织内部的TIL细胞、规模扩增并注入患者体内发挥疗效。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-12-17/doc-inhcavhm7560592.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4211","ORR","BK4107","BK4588","BK4139","LU0053666078.USD","LU2487616109.SGD","BK4505","BK4195","L","BK4585","TIL","LU0210528500.USD","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590394122","title":"新股前瞻|布局TCE肿瘤疗法千亿蓝海，时迈药业能否博得市场青睐？","url":"https://stock-news.laohu8.com/highlight/detail?id=2590394122","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590394122?lang=zh_cn&edition=fundamental","pubTime":"2025-12-09 13:05","pubTimestamp":1765256702,"startTime":"0","endTime":"0","summary":"近日，又一创新药企正式向港交所提交上市申请。在此背景下，作为一家专注于实体瘤TCE疗法、且具备多款全球前列临床管线的企业，时迈药业的上市进程亦自然备受瞩目。布局TCE疗法 四款创新药物处于临床阶段智通财经APP了解到，时迈药业目前仍处于临床研发阶段，并无产品商业化。根据时迈药业招股书披露，当前仅有两款用于实体瘤的TCE药物获得全球批准，市场存在大量空白，这为具备相关布局能力的创新药企提供了结构性机遇。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ORR","CRS","BK4231","LU0053666078.USD","ADC","LU2487616109.SGD","BK4585","IE0031619046.USD","LU2065731478.USD","BK4187","BK4080","IE00B66KJ199.SGD","BK4006","LU0963586101.USD","IE00B7SZL793.SGD","L","LU0210528500.USD","BK4107","IE00B19Z4B17.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590451393","title":"吉利德Anito-cel 神经毒性低，2年多发性骨髓瘤生存率高 | ASH25","url":"https://stock-news.laohu8.com/highlight/detail?id=2590451393","media":"Minhua笔记","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590451393?lang=zh_cn&edition=fundamental","pubTime":"2025-12-08 11:58","pubTimestamp":1765166299,"startTime":"0","endTime":"0","summary":"在ASH 2025年会上，吉利德旗下Kite Pharma公布Anito-cel在iMMagine-1 II期试验中的更新数据，该靶向BCMA的CAR-T疗法在复发/难治性多发性骨髓瘤患者中显示96% ORR、74% sCR/CR率、95% MRD阴性率，中位随访15.9个月，缓解持续。III期iMMagine-3试验正在招募中，该研究将Anito-cel与标准治疗比较，预计2026年获得数据；该药物获FDA快速通道、孤儿药和RMAT资格。ICANS 发生率为 8%，其中 1 例为 3 级；其余均为 2 级或更低。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208144817a43ac231&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208144817a43ac231&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1778281490.HKD","BK4588","BK4139","IE0002270589.USD","BK4550","BK4532","CRS","IE00B19Z3B42.SGD","IE00B3T34201.USD","BK4578","IE00B66KJ199.SGD","ASH","LU1674673691.USD","IE00B7SZLL34.SGD","PFS","IE00BKVL7J92.USD","LU0109394709.USD","BK4109","LU1571399168.USD","IE00B19Z4B17.USD","LU1585245621.USD","LU0289739699.SGD","SG9999015945.SGD","CR","BK4097","LU1430594728.SGD","ORR","SG9999015952.SGD","IE00BZ1G4Q59.USD","LU1066051498.USD","LU0889565916.HKD","IE00B7SZL793.SGD","LU1674673428.USD","BK4187","GILD","BK4568","KOL","LU0234570918.USD","LU0320765992.SGD","BK4195","IE00B19Z3581.USD","BK4585","LU0823416689.USD","LU0882574055.USD","LU1839511570.USD","SG9999015978.USD","OS","SG9999015986.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584941686","title":"iza-bren食管鳞癌Ⅲ期临床期中分析迎关键突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2584941686","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584941686?lang=zh_cn&edition=fundamental","pubTime":"2025-11-19 21:09","pubTimestamp":1763557767,"startTime":"0","endTime":"0","summary":"在创新药研发的竞技场上，Ⅲ期临床的“期中大考”是检验药物价值的试金石。11月18日，百利天恒（SH688506，股价369.30元，市值1525.00亿元）宣布其核心产品——全球首创的EGFR×HER3双抗ADC（抗体药物偶联物）药物izabren，在晚期食管鳞癌Ⅲ期临床试验的预设期中分析中，同时达到无进展生存期和总生存期双主要终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511193569015549.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511193569015549.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","ORR","BK4211","OS","02615","BK4195","PFS","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2583441513","title":"一哥新高，要起风了","url":"https://stock-news.laohu8.com/highlight/detail?id=2583441513","media":"CPHI制药在线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583441513?lang=zh_cn&edition=fundamental","pubTime":"2025-11-13 18:03","pubTimestamp":1763028209,"startTime":"0","endTime":"0","summary":"关注并星标CPHI制药在线百济神州三季报交上了一份高分的答卷，2025年第三季度，百济神州实现营收14.12亿美元，同比去年第三季度增长41%；2025年前三季度，百济神州实现营收38.45亿美元，同比去年前三季度增长43%。最近一次获批是在2024年3月7日，批准治疗复发或难治性滤泡性细胞瘤。百济神州目前的战略是三位一体，用泽布替尼，Bcl-2抑制剂索托克拉以及BTK为靶点的PROTAC药物，来维持其在CLL适应症乃至整个血液疾病适应症的地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113191029a6f6e18c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113191029a6f6e18c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2106854487.HKD","LU2355687059.USD","LU2211814178.USD","LU1917777945.USD","IE00BYQQ9H92.USD","LU2125910179.SGD","LU1712237335.SGD","BK4588","LU2211817866.USD","LU2229751404.USD","LU2463526074.USD","LU1093756325.SGD","LU2041044095.USD","06160","LU1585245621.USD","LU2240825500.USD","BK4566","LU1093756168.USD","LU0511384066.AUD","WM","LU0289739343.SGD","LU1974910355.USD","BK4526","LU2238339852.HKD","LU2413666426.HKD","IE00BFXG0V08.USD","BK4120","MTD","BK4139","LU0289961442.SGD","LU0689626769.HKD","LU2362540622.SGD","LU0347712357.USD","ONC","LU0175139822.USD","LU1623119135.USD","LU0124676726.USD","LU1923621640.USD","LU2298064838.USD","LU2023250504.SGD","LU2089279066.USD","ORR","LU0057025933.USD","BK4121","LU2125910336.SGD","BK4534","LU0472753341.HKD","LU0069063385.USD","LU2413666699.HKD","LU0289960550.SGD","LU1430594728.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2582034364","title":"药企豪赌 肺癌下一代免疫“新药王”争夺赛已打响","url":"https://stock-news.laohu8.com/highlight/detail?id=2582034364","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582034364?lang=zh_cn&edition=fundamental","pubTime":"2025-11-12 11:29","pubTimestamp":1762918190,"startTime":"0","endTime":"0","summary":"【药企豪赌 肺癌下一代免疫“新药王”争夺赛已打响】凭借在肺癌领域的突出表现，默沙东的PD-1单抗K药连续在2023年、2024年成为全球药王，年销售额均突破200亿美元。谁能成为肺癌领域下一代免疫“新王”，一场争夺赛在药企中已打响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511123562061651.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511123562061651.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0053666078.USD","BK4107","LU0348827113.USD","LU0348784397.USD","LU0561508036.HKD","LU2778985437.USD","LU2097828474.EUR","LU1794554557.SGD","LU0455707207.USD","BK4585","LU0540923850.HKD","LU2487616109.SGD","BK1589","BK1574","LU2399975544.HKD","LU0210528500.USD","LU2328871848.SGD","HK0000165453.HKD","BK4588","LU0348783233.USD","LU0417516738.SGD","LU1961090484.USD","LU2097828714.EUR","LU0348766576.USD","LU1969619763.USD","LU2476274308.USD","LU0348767384.USD","BK1161","LU2097828557.USD","LU1720050803.USD","LU2476274720.SGD","LU2242644610.SGD","LU2488822045.USD","LU2097828631.EUR","LU0348735423.USD","01801","IE00BPRC5H50.USD","02696","LU0417516902.SGD","LU0417516571.SGD","IE00B5MMRT66.SGD","LU0634319403.HKD","LU2097828805.USD","LU0348825331.USD","ORR","BK1583","09926","IE00B543WZ88.USD","LU0502904849.HKD","L"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2582371841","title":"招银国际：医药业关注布局思路更偏稳健 低估值个股机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2582371841","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582371841?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 13:43","pubTimestamp":1762753386,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，布局思路更偏稳健，关注低估值个股机会。招银国际主要观点如下：MSCI中国医疗指数2025年初至今累计上涨59.5%，跑赢MSCI中国指数24.0%近期，医药板块有所回调，该行认为部分低估值个股具备吸引力。辉瑞管理层表示即将公布707的完整研发计划。此次医保谈判结果预计12月初公布。本轮集采的平均价格降幅并未公布。该行认为仿制药仍将长期维持较低利润率水平。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367136.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","BK1515","BK1141","01801","LU2242644610.SGD","BK1574","BK1593","LU0502904849.HKD","LU2097828557.USD","LU1969619763.USD","LU0455707207.USD","IE00BZ08YT58.USD","BK1161","SG9999004311.SGD","02268","06978","SG9999014674.SGD","BK1207","02273","LU2097828474.EUR","LU2097828805.USD","IE00BZ08YR35.GBP","01177","BK1191","02367","LU2328871848.SGD","ORR","LU2097828631.EUR","IE00BZ08YS42.EUR","HK0000165453.HKD","BK1521","LU2097828714.EUR","BK1583","LU2488822045.USD","01530","BK1219"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2577639389","title":"安科生物披露创新药HuA21注射液在2025年欧洲肿瘤内科学会年会公布临床研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2577639389","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577639389?lang=zh_cn&edition=fundamental","pubTime":"2025-10-21 08:53","pubTimestamp":1761007995,"startTime":"0","endTime":"0","summary":"格隆汇10月21日丨安科生物公布，公司于2025年10 月 17 日至 21 日在德国柏林召开的欧洲肿瘤内科学会年会上，以壁报形式公布自主研发的生物创新药重组抗 HER2 人源化HuA21 单克隆抗体注射液联合曲妥珠单抗和化疗治疗HER2 阳性晚期胃/胃食管交界处腺癌 Ib/II 期剂量递增和扩展研究的最新研究成果。HuA21 通过诱导 HER2 受体的内吞和下调，打断癌细胞信号通路，从而抑制癌细胞生长和增殖，产生促进癌细胞凋亡、抗肿瘤血管生成等效果，最终达到抑制肿瘤的作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021085601a6c4ac4d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021085601a6c4ac4d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4218","ORR","PK","BK4019","KG","BK4181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2575701254","title":"FAK赛道处于爆发前夜！应世生物深耕布局，全球领跑","url":"https://stock-news.laohu8.com/highlight/detail?id=2575701254","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575701254?lang=zh_cn&edition=fundamental","pubTime":"2025-10-14 12:29","pubTimestamp":1760416190,"startTime":"0","endTime":"0","summary":"协同管线布局，拓展治疗边界为巩固赛道领先地位，应世生物还布局了第二代选择性FAK抑制剂IN10028，依托ifebemtinib的研发经验，优化与RAS抑制剂、ADC等疗法的协同效果，计划于2025年第四季度提交IND申请，2026年启动首次人体临床试验。Ifebemtinib有望成为同类最佳的选择性FAK抑制剂，凭借ifebemtinib的先发优势与协同管线布局，应世生物有望在这一蓝海市场中占据领先地位。截至2025年3月末，公司账上的现金及","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1760316553550547598","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU2039709279.SGD","BK4567","TME","PROC","BK4224","IE00BYTNYN87.SGD","BK4588","BK4552","IE00BYQNZ168.SGD","BK4509","PLD","BK4531","SG9999011746.SGD","BK4534","LU0359202008.SGD","IE00B12V2V27.USD","BK4171","BK4563","BK4565","BK4535","BK4108","BK4007","LU0359201612.USD","BK4585","BK4571","BK4526","ORR","LU1023057109.AUD","BK4548","01698","LU0456842615.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2574538681","title":"药明巨诺：国产病毒载体版倍诺达补充申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2574538681","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574538681?lang=zh_cn&edition=fundamental","pubTime":"2025-10-09 17:48","pubTimestamp":1760003334,"startTime":"0","endTime":"0","summary":"10月9日，药明巨诺（02126）发布公告，中国国家药品监督管理局已正式受理公司倍诺达?使用国产病毒载体的上市后补充申请。此次申请基于一项II期单臂研究，旨在评估使用新工艺病毒载体（JWLV011）生产的瑞基奥仑赛注射液与现有病毒载体生产的产品可比性。研究结果显示，3个月最佳客观缓解率（ORR）为66.67%，疾病完全缓解率（CR）为41.67%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510093529591131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ORR","BK4161","CR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":30,"code":"91000000","status":"200"}]}}